Davis Polk advised the representatives of the several purchasers in offering. Ionis Pharmaceuticals, Inc. executed its offering of an aggregate principal amount of $632.5 million of its...
Ionis Pharmaceuticals’ $632.5 Million Convertible Senior Notes Offering
Maravai LifeSciences’s $646.9 Million Secondary Offering
Davis Polk advised the joint book-running managers in the offering. The $646.9 million secondary offering of 20,700,000 shares of common stock of Maravai LifeSciences Holdings, Inc....
Beam Therapeutics’ $300 Million At-The-Market Offering
Davis Polk advised Jefferies, the sales agent, in the transaction. Beam Therapeutics Inc. executed the at-the-market offering of shares of its common stock for up to a...
Bridgepoint’s Acquisition of Sun World International
Davis Polk advised Bridgepoint Capital on the deal. Bridgepoint Capital executed its acquisition of Sun World International. Financial terms of the transaction were not disclosed. Bridgepoint...
Solid Biosciences’ $143.75 Million Equity Offering
Davis Polk advised the joint book-running managers in the offering. Solid Biosciences Inc. executed the $143.75 million public offering of common stock. The common stock is listed...
Nurix Therapeutics’ $160.4 Million Follow-on Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in the offering. Nurix Therapeutics, Inc. completed its follow-on offering of 5,175,000 shares...
Adamas Pharmaceuticals’ $59 Million Stock Offering
Davis Polk advised the joint book-running managers in the offering. Adamas Pharmaceuticals, Inc. executed its $59 million follow-on offering of 14,375,000 shares of common stock, which included...
Evernorth’s Acquisition of MDLIVE
Davis Polk advised MDLIVE on the deal. MDLIVE, Inc. executed its acquisition by Evernorth. The transaction, which is expected to close in the second quarter of...
Charles River Laboratories’ $875 Million Acquisition of Cognate BioServices
Davis Polk and Hannes Snellman advised Charles River Laboratories International on the deal. Weil, Gotshal & Manges advised Charles River Laboratories on the antitrust aspects of...
Biogen’s $1.75 Billion Exchange Offer
Davis Polk advised the dealer managers in the deal. Biogen Inc. (Nasdaq: BIIB) announced the commencement of a private offer to exchange any and all of its...